- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and clinical diagnostics products, for the commercializati ...

Bio-Rad (BIO) suffers due to funding issue within BioPharma, macroeconomic headwinds and competitive pressures. The stock carries a Zacks Rank #4 (Sell) at present.Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, wherein the demand for life science products has been strong historically. This directly correlates with the funding constraints that the broader pharmaceutical industry has started to experience. Management puts forth that BioPharma’s softness has r ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s management will participate in a fireside chat event during Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024, at 2:30 PM Eastern Time (11:30 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s ...

Bio-Rad Laboratories, Inc. (BIO) posted fourth-quarter 2023 adjusted earnings per share (EPS) of $3.10, beating the Zacks Consensus Estimate by 5.8%. However, the bottom line declined 6.3% from the prior-year quarter’s levels.The quarter’s adjustments eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, Restructuring costs, gains/losses from the change in the fair market value of equity securities and gains/losses on equity-method investments.The company’s GAA ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2023 Earnings Conference Call February 15, 2024 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Conor McNamara - RBC Capital Markets Andy Last - Executive Vice President and COO Simon May - President, Life Science Group Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Dan Leonard - UBS Finally, our remarks today will include references to non-GAAP financials, includin ...

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.0 million and $4.1 million in the consolidated statements of income (loss) for the year ended December 31, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of Dece ...

Bio-Rad Laboratories, Inc. (BIO) is set to release fourth-quarter 2023 results on Feb 15 after the closing bell.The company posted adjusted earnings per share (EPS) of $2.33 in the last reported quarter, missing the Zacks Consensus Estimate by 18.8%. Bio-Rad beat earnings estimates in three of the trailing four quarters and missed the same in one, the average negative surprise being 0.54%.Let’s look at how things have shaped up before this announcement.Factors at PlayLife ScienceThe Life Science segment is ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 888-259-6580 within the U.S. or +1 416-764-8624 outside the U.S., ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET Question-and-Answer Session Jack Meehan - Nephron We have also excluded certain items below the operating line, which are the increase in value of the Sartorius equity securities and loan receivable holdings of $36.4 million, $2.5 million gain from the release of an escrow for an acquisition and about a $700,000 loss associated with venture investments. Thank you, Ilan. So, I guess, I just wanted to take a minu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-138 ...